Hong Kong’s Aprinoia Therapeutics to go public via SPAC merger

Hong Kong’s Aprinoia Therapeutics to go public via SPAC merger

Photo by Pepi Stojanovski on Unsplash

Aprinoia Therapeutics, a clinical-stage neuroscience biotech company, has agreed to go public in the US through a business combination with a publicly-traded special purpose acquisition company (SPAC) Ross Acquisition Corp II.